New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis | Johnson & Johnson

New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis

10/15/2020

DownloadPDF 195 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com